1Grubbs CJ, Lubet RA, Koki AT, et al. CeleCOXib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res , 2000, 60:5599-5602.
2Shirahama T. Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder. Clin Cancer Res,2000, 6:2424-2430.
3Watson AJ. Chemopreventive effects of NSAIDs against colorectal cancer: regulation of apoptosis and mitosis by COX-1 and COX-2. Histol Histopathol,1998, 13:591-597.
4Tsujii M, Kawano S, Tsuji S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell, 1998, 93:705-716.
5O′Mahony CA, Beauchamp RD, Albo D, et al. Cyclooxygenase-2 alters transforming growth factor-beta 1 response during intestinal tumorigenesis. Surgery, 1999, 126:364-370.
6Komhoff M, Guan Y, Shappell HW, et al. Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas. Am J Pathol, 2000, 157:29-35.
7Shirahama T, Arima J, Akiba S, et al. Relation between cyclooxygenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder. Cancer, 2001, 92:188-193.
8El-Sheikh SS, Madaan S, Alhasso A, et al. Cyclooxygenase-2: a possible target in schistosoma-associated bladder cancer. BJU Int, 2001, 88:921-927.
9Kim SI, Kwon SM, Kim YS, et al. Association of cyclooxygenase-2 expression with prognosis of stage T1 grade 3 bladder cancer. Urology, 2002, 60:816-821.
10Bostrom PJ, Aaltonen V, Soderstrom KO, et al. Expression of cyclooxygenase-1 and -2 in urinary bladder carcinomas in vivo and in vitro and prostaglandin E2 synthesis in cultured bladder cancer cells. Pathology, 2001, 3:469-474.
同被引文献15
1Smolian H, Aurer A, Sittinger M, et al. Secretion of gelatinases and activation of gelatinase A (MMP-2) by human rheumatoid synovial fibroblasts. Biol Chem, 2001, 382:1491-1499.
2Roshak A, Mochan E, Marshall LA. Suppression of human synovial fibroblast 85 kDa phospholipase A2 by antisense reduces interleukin-1 beta induced prostaglandin E2. J Rheumatol, 1996, 23:420-427.
3Martel-Pelletier J, Pelletier JP, Fahmi H. Cyclooxygenase-2 and prostaglandins in articular tissues. Semin Arthritis Rheum, 2003, 33:155-167.
4Alaaeddine N, DiBattista JA, Pelletier JP, et al. Osteoarthritic synovial fibroblasts possess an increased level of tumor necrosis factor-receptor 55 (TNF-R55) that mediates biological activation by TNF-alpha. J Rheumatol, 1997, 24:1985-1994.
5Edwards JC. Fibroblast biology. Development and differentiation of synovial fibroblasts in arthritis. Arthritis Res, 2000, 2:344-347.
6Milam SB, Schmitz JP. Molecular biology of temporomandibular joint disorders: proposed mechanisms of disease. J Oral Maxillofac Surg, 1995, 53:1448-1454.
7Stevens CR, Blake DR, Merry P, et al. A comparative study by morphometry of the microvasculature in normal and rheumatoid synovium. Arthritis Rheum, 1991, 34:1508-1513.
8Bodamyali T, Stevens CR, Billingham ME, et al. Influence of hypoxia in inflammatory synovitis. Ann Rheum Dis, 1998, 57: 703-710.
9Smith WL, Langenbach R. Why there are two cyclooxygenase isozymes. J Clin Invest, 2001, 107:1491-1495.
10Myers LK, Kang AH, Postlethwaite AE, et al. The genetic ablation of cyclooxygenase 2 prevents the development of autoimmune arthritis. Arthritis Rheum, 2000, 43:2687-2693.
